Pipeline

Pipeline

//aruvant.com/wp-content/uploads/2019/03/AruvantPipeline.png

ARU-1801

Aruvant’s lead product candidate, ARU-1801, is a potentially curative gene therapy for individuals living with sickle cell disease (SCD) and beta-thalassemia. ARU-1801 is administered once and designed to address the limitations of current curative treatment options, such as low donor availability and chemotherapy conditioning toxicity. ARU-1801 is currently under clinical investigation, and has demonstrated durable, meaningful clinical responses to date for patients with SCD, while only requiring reduced intensity conditioning. ARU-1801 is in an ongoing study that is actively recruiting patients. Click here for more information or email clinicaltrials@aruvant.com.